S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

$2.12
+0.16 (+7.91%)
(As of 12:16 PM ET)
Today's Range
$1.99
$2.14
50-Day Range
$1.95
$2.97
52-Week Range
$1.82
$13.20
Volume
31,725 shs
Average Volume
156,611 shs
Market Capitalization
$1.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Cyclacel Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
950.0% Upside
$21.00 Price Target
Short Interest
Healthy
2.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Cyclacel Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($18.70) to ($3.24) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

CYCC stock logo

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CYCC Stock Price History

CYCC Stock News Headlines

Cyclacel Pharmaceuticals Inc
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals Inc. (UXI.SG)
Cyclacel Pharmaceuticals Announces Reverse Stock Split
Cyclacel Pharmaceuticals Inc CYCC
See More Headlines
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+950.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-22,560,000.00
Pretax Margin
-6,083.57%

Debt

Sales & Book Value

Annual Sales
$420,000.00
Book Value
$0.72 per share

Miscellaneous

Free Float
772,000
Market Cap
$1.68 million
Optionable
Optionable
Beta
0.56
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

CYCC Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYCC shares.
View CYCC analyst ratings
or view top-rated stocks.

What is Cyclacel Pharmaceuticals' stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Cyclacel Pharmaceuticals' stock. Their CYCC share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 950.0% from the stock's current price.
View analysts price targets for CYCC
or view top-rated stocks among Wall Street analysts.

How have CYCC shares performed in 2024?

Cyclacel Pharmaceuticals' stock was trading at $2.67 at the start of the year. Since then, CYCC stock has decreased by 25.1% and is now trading at $2.00.
View the best growth stocks for 2024 here
.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 26,600 shares, a drop of 35.9% from the February 29th total of 41,500 shares. Based on an average daily volume of 163,500 shares, the days-to-cover ratio is currently 0.2 days. Currently, 2.2% of the company's stock are sold short.
View Cyclacel Pharmaceuticals' Short Interest
.

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CYCC earnings forecast
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) released its quarterly earnings data on Monday, March, 6th. The biotechnology company reported ($9.00) EPS for the quarter, missing analysts' consensus estimates of ($7.20) by $1.80.

When did Cyclacel Pharmaceuticals' stock split?

Cyclacel Pharmaceuticals's stock reverse split before market open on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Point72 Asset Management L.P. (1.83%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Paul Mcbarron, Sam L Barker and Spiro George Rombotis.
View institutional ownership trends
.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYCC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners